Approval · Notice of Compliance 836 · 2001
ZIAGEN: Notice of Compliance 836
Issued September 10, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 836
- Date
- September 10, 2001
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Replaces the notice of compliance with conditions issued on june 4, 1999
- Therapeutic class
- Antiretroviral agent
Products in this notice
Medicinal ingredients
- ABACAVIR SULFATE 300 MG per TAB
- ABACAVIR SULFATE 20 MG per ML